Scottish Medicines Consortium recommends Eisai’s Kisplyx for advanced kidney cancer
pharmafile | November 12, 2019 | News story | Manufacturing and Production, Sales and Marketing | Eisai, Kisplyx, NHS, Sotland, pharma
Eisai’s Kisplyx (lenvatinib) has secured recommendation from the Scottish Medicines Consortium, it has been revealed, meaning that patients on the NHS in Scotland will soon be able to access the drug for the treatment of advanced kidney cancer.
Specifically, the drug is authorised in combination with everolimus for the treatment of advanced renal cell carcinoma (RCC) in adult patients who have received one prior vascular endothelial growth factor (VEGF)-targeted therapy.
In data drawn from 153 advanced RCC patients, the combo extended median progression-free survival of 14.6 months, compared to just 5.5 months with everolimus alone, while median overall survival was shown to be 25.5 months versus 15.4 months.
“This is great news for patients with advanced kidney cancer in Scotland,” commented Professor Robert Jones, Professor of Clinical Cancer Research at the University of Glasgow. “It’s particularly pleasing that the lenvatinib and everolimus combination is now available, as patients in Glasgow have been involved in the clinical trials over several years. As a result of their contribution the benefits of lenvatinib can now be extended to other Scottish patients with advanced RCC.”
Maureen Johnson, Kidney Cancer Scotland’s Health Professional, also remarked: “We are delighted that the SMC is recommending lenvatinib in combination with everolimus as a second line treatment for patients with advanced renal cell carcinoma. This news will be welcomed by patients and their families, who can be assured that NHS Scotland has access to this clinically effective combination to support their treatment.”
Scottish patients now join English and Welsh patients in accessing Kisplyx; NICE chose to recommend the drug back at the end of 2017 and it has been available in those regions since December of that year.
Matt Fellows
Related Content
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
Eisai shares new data for Leqembi for Alzheimer’s treatment
Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL …
Novo Nordisk launches Wegovy in the UK
Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …
